The Department of Justice and the Federal Trade Commission have announced a civil enforcement action against Xlear Inc. and its CEO Nathan Jones for alleged violations of the COVID-19 Consumer Protection Act and the FTC Act.

The complaint was filed in Utah, according to a DOJ statement, and alleges that Xlear advertised that its saline nasal spray could prevent or treat COVID-19, without any credible scientific data to back it up. The government also claimed the defendants made deceptive statements about several scientific studies to bolster their claims that the spray could prevent COVID-19.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]